Articles tagged "Liver transplantation"

2015 American Transplant Congress
Validation of the Model for End-Stage Liver Disease Score Criteria in Liver Transplantation for Acute Flare Up of Hepatitis B in Non-Cirrhotic Liver
W.-C. Lee,¹ T.-J. Wu,¹ C.-F. Lee,¹ R.-S. Soong,¹ C.-H. Cheng,¹ H.-S. Chou,¹ T.-H. Wu,¹ K.-M. Chan,¹ Y.-C. Wang,¹ C.-S. Lee.²
¹Liver and Transplantation Surgery, Chang-Gung Memorial Hospital, Chang-Gung University College of Medicine, Taoyuan, Taiwan; ²Hepatology, Chang-Gung Memorial Hospital, Chang-Gung University College of Medicine, Taoyuan, Taiwan.
Background: Decision of necessity of urgent liver transplantation for acute flare up of hepatitis B in the patients without cirrhosis is difficult. The MELD score…
2015 American Transplant Congress
Bridging Therapy With Belatacept in High MELD Liver Transplant Recipients
T. Sparkes,¹ B. Masters,¹ S. Hanish,² D. Potosky,² W. Hutson,² J. LaMattina,² R. Barth.²
¹University of Maryland Medical Center, Baltimore; ²University of Maryland School of Medicine, Baltimore.
Background: Poor outcomes of high-MELD liver transplant recipients are driven by multisystem organ dysfunction. Renal failure post-transplant has been associated with mortality of greater than…
2015 American Transplant Congress
Pre-Transplant Portal Vein Recanalization-Transjugular Intrahepatic Portosystemic Shunt in Patients With Chronic Portal Vein Thrombosis
B. Thornburg, K. Desai, T. Baker, J. Fryer, M. Abecassis, J. Caicedo, L. Kulik, R. Salem.
Northwestern Memorial Hospital, Chicago, IL.
Background: Chronic, occlusive portal vein thrombosis (PVT) associated with cirrhosis represents a relative contraindication to liver transplantation (LT) in some centers. From a surgical perspective,…
2015 American Transplant Congress
Incidence and Impact of De Novo Donor-Specific Anti-HLA Antibodies in ABO-Compatible Liver-Transplant Recipients
A. Del Bello,^1,2 N. Congy-Jolivet,^2,3,4 D. Milongo,¹ C. Guilbeau-Frugier,^2,5 L. Lavayssière,¹ F. Muscari,^2,6 L. Rostaing,^1,2,7 N. Kamar.^1,2,7
¹Department of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France; ²Université Paul Sabatier, Faculté de Médecine, Toulouse, France; ³Molecular Immunogenetics Laboratory, EA 3034, Faculté de Médecine Purpan, IFR150, Toulouse, France; ⁴Department of Immunology, CHU Rangueil, Toulouse, France; ⁵Department of Pathology, CHU Rangueil, Toulouse, France; ⁶Surgery and Liver Transplantation, CHU Rangueil, Toulouse, France; ⁷INSERM U1043, IFR–BMT, CHU Purpan, Toulouse, France.
Background: The incidence and consequences of de novo donor-specific anti-HLA antibodies (DSAs) after liver transplantation (LT) are not well known. Thus, we investigated the incidence,…
2015 American Transplant Congress
HO-1 Modified Macrophages Promote Autophagy by Activating Sirt1/TGF-β/Smad4 Signaling in Ischemia-Stressed Mouse Liver Transplants
S. Yue, J. Huang, K. Nakamura, M. Zhou, X.-D. Shen, R. Busuttil, B. Ke, J. Kupiec-Weglinski.
Dumont-UCLA Transplant Ctr, Dept. of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Background: Although heme oxygenase-1 (HO-1) is known to induce alternative macrophage activation towards an anti-inflammatory M2 phenotype, the underlying mechanisms remain elusive. Autophagy may play…
2015 American Transplant Congress
Biliary Complication After Living Donor Liver Transplantation According to Biliary Reconstruction Methods
J. Lee,^1,2 J. Lee,^1,2 D. Han,^1,2 J. Lee,³ M. Ju,^1,2 M. Kim,^1,2 G. Choi,^1,2 J. Choi,^1,2 S. Kim,^1,2 D. Joo.^1,2
¹Department of Surgery, Yonsei University College of Medicine, Seoul, Korea; ²The Research Institute for Transplantation, Yonsei University College of Medicine, Seoul, Korea; ³Department of Surgery, CHA Bundang Medical Center, CHA University, Bundang, Korea.
BackgroundDespite improvement of operative techniques and long term outcomes, biliary complication remains as a severe obstacle in living donor liver transplantation.MethodsMedical records of 245 adult…
2015 American Transplant Congress
Racial Disparities in Living Donor Liver Transplantation
Y. Nobel,¹ K. Forde,² L. Wood,³ P. Yoo,⁴ P. Abt,³ D. Goldberg.²
¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; ²Department of Medicine, University of Pennsylvania, Philadelphia, PA; ³Division of Transplant Surgery, Department of Surgery, University of Pennsylvania, Philadelphia, PA; ⁴Department of Surgery, Yale University School of Medicine, New Haven, CT.
Purpose: Living donor liver transplantation (LDLT) is an alternative to deceased donor transplantation (DDLT), and can mitigate the risk of dying while waiting for transplant.…
2015 American Transplant Congress
Preventing Cytomegalovirus Infection in Intermediate-High Risk Liver Transplant Recipients: Acyclovir Vs Valganciclovir
S. Dulanya, A. Anamisis, D. Tsapepas.
Department of Pharmacy, New York Presbyterian Hospital, New York City, NY.
Cytomegalovirus (CMV) is an opportunistic infection responsible for profound morbidity and mortality among solid organ transplant recipients. A donor and recipient's CMV IgG serostatus influences…
2015 American Transplant Congress
An Orchestrated Sequence of Innate and Adaptive Immune Responses Is Associated With Rejection After Pediatric Liver Transplantation
C. Falk,¹ I. Goldschmidt,² F. Mutschler,² C. Neudörfl,¹ J. Keil,¹ K. Daemen,¹ F. Lehner,³ R. Mikolajzcyk,⁴ A. Karch,⁴ U. Baumann.²
¹Institute of Transplant Immunology, IFB-Tx, Hannover Medical School, Hannover, Germany; ²Division of Pediatric Gastroenterology and Hepatology, Hannover Medical School, Hannover, Germany; ³Department of Visceral General and Transplant Surgery, Hannover Medical School, Hannover, Germany; ⁴Department of Epidemiology, Helmholtz Center for Infection Research, HZI, Braunschweig, Braunschweig, Germany.
The concept of a coordinated immune response initiated by innate and sustained by adaptive immune cells and their soluble mediators is well established for infection…
2015 American Transplant Congress
Long-Term Outcome After Liver Transplantation for Unresectable Hepatocellular Carcinoma Following Yttrium-90 Radioembolization Bridging Treatment
S. Radunz,¹ T. Benkoe,¹ J. Best,² A. Bockisch,³ T. Lauenstein,⁴ H. Baba,⁵ A. Paul,¹ J. Treckmann.¹
¹General, Visceral and Transplantation Surgery, University Hospital Essen, Essen, Germany; ²Gastroenterology and Hepatology, University Hospital Essen, Essen, Germany; ³Nuclear Medicine, University Hospital Essen, Essen, Germany; ⁴Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany; ⁵Pathology and Neuropathology, University Hospital Essen, Essen, Germany.
Background: Liver transplantation remains the only curative treatment option for patients with unresectable hepatocellular carcinoma (HCC). Several bridging treatments are employed because the limited availability…